DECN to Offer New Bundling for its Products, Starting with Offering a 90-Day Supply of GenUltimate! Test Strips in a Single Box for $38.95
Designed for Sales on Amazon, Walmart and 1000+ Other Commerce Sites, our “90-Day Pack” Offers Substantial Convenience for Diabetics Covered by Medicare and Medicaid, as well as Uninsured and Under-Insured Diabetics
LOS ANGELES, CA / ACCESSWIRE / December 17, 2019 / Decision Diagnostics Corp. (OTC PINK:DECN) is a 17-year old, diabetes-focused bio-technology development firm, manufacturer, quality plan administrator, FDA registered medical device customer support organization, and exclusive worldwide sales and regulatory process agent for the GenUltimate! (“Sunshine”) diabetes test strip, the GenSure! (“Feather”) diabetes test strip for International markets, and its GenChoice! (“Ladybug”) test strip now in FDA 510(k) prosecution. The company also markets its PetSure! test strip for the diabetic testing of dogs and cats, a diagnostic specifically designed to run on the market leading Zoetis Alpha Trak meter system and the GenUltimate! 4Pets Test strip and Avantage! meter a proprietary testing product for dogs, cats and horses, and the panacea GenUltimate! TBG (“Dragonfly”) diabetes testing system, now awaiting a clinical trial slot in Korea.
DECN announces today that at the request of several of its larger distributors and through Amazon and Walmart the company has been asked to create new bundles of its GenUltimate! test strips in a “90 day” package of 250 test strips. Both of the Medicare and Medicaid systems have adopted procedures that allow, even encourage, diabetics to limit their trips to the pharmacy now that the mail order fulfillment alternatives have greatly declined.
Keith Berman, CEO of DECN commented, “The average Type II diabetic tests 2.7 times each day. A “90 day pack” of 250 GenUltimate! test strips will be a big winner and will open the door to allow us to capture a market where we can dominate on price and convenience. In addition to the direct to patient pharmacy markets, our “90-day pack” will also allow our distributors to create on-line listings for fulfillment via subscription service, a feature that has declined in the market along with the fall-off of mail order fulfillment services.”
Mr. Berman continued, “We expect the “90 day pack” to create new business while continuing a trend of eating into in-store retail sales of diabetic test strips. This new pack and its addition to our business model will be available for sale on Amazon and Walmart, and the over 1000 other sites, early in January 2020. TV commercial advertising will also commence at this time.”
Mr. Berman concluded, “We will add the “90 day pack” throughout our product line as we bring our products to market. The most exciting benefit of this pack is its profitability, almost 3X the level of GenUltimate! 50 and 100 per box (unit) and 2X the level of profit percent per box.”
ABOUT DECISION DIAGNOSTICS CORP
Decision Diagnostics Corp. is the leading manufacturer and worldwide distributor of diabetic test strips engineered to operate on legacy glucose meters. DECN’s products are designed to operate efficiently and less expensively on certain glucose meters already in use by almost 7.5 million diabetics worldwide. With new inspired technology diabetic test strips already in the final stages of development, DECN products compete on a worldwide scale with legacy manufacturers currently selling to 71+ percent of a $15+ billion at-home testing market. The company’s GenUltimate TBG product is not yet available for sale in the United States or Puerto Rico but is expected to go on sale in select International markets in January 2020.
This release contains the company’s forward-looking statements which are based on management’s current expectations and assumptions as of December 16, 2019 regarding the company’s business and performance, its prospects, current factors, the economy, and other future conditions and forecasts of future events, circumstances, and results.
Decision Diagnostics Corp.
Keith Berman (805) 446-2973
SOURCE: Decision Diagnostics Corp.
View source version on accesswire.com: